Brigatinib
Brigatinib (AP-26113) is a potent and selective small-molecule inhibitor of anaplastic lymphoma kinase (ALK) . It is widely used in preclinical research, demonstrating efficacy in both in vitro cellular assays and in vivo models of ALK-positive cancers, particularly non-small cell lung carcinoma (NSCLC) .
Product Specifications
CAS Number
1197953-54-0
Product Name Alternative
AP26113
Field of Research
Cardiovascular Research, Immunology & Inflammation, Pharmacology & Drug Discovery, Signal Transduction
Purity
>98%
Bioactivity
Pan-ALK inhibitor
Form
Powder
Solubility
Soluble in DMSO (up to 1 mg/ml, warm)
Smiles
COc1cc (ccc1Nc1ncc (Cl) c (Nc2ccccc2P (C) (C) =O) n1) N1CCC (CC1) N1CCN (C) CC1
Molecular Formula
C29H39ClN7O2P
Molecular Weight
584.1
Storage Conditions
-20°C
Notes
For research use only.
Other Product Names
5-Chloro-N4-[2- (dimethylphosphinyl) phenyl]-N2-[2-methoxy-4-[4- (4-methyl-1-piperazinyl) -1-piperidinyl]phenyl]-2,4-pyrimidinediamine
Available Sizes
Frequently Asked Questions
Explore Other Products
Browse additional items from our catalog
Rabbit anti-Escherichia coli O157:H7 FOCA Polyclonal Antibody